Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Formative Research

Date Submitted: Aug 22, 2022
Date Accepted: Oct 29, 2022
Date Submitted to PubMed: Oct 29, 2022

The final, peer-reviewed published version of this preprint can be found here:

The Incidence and Effect of Adverse Events Due to COVID-19 Vaccines on Breakthrough Infections: Decentralized Observational Study With Underrepresented Groups

Gabashvili I

The Incidence and Effect of Adverse Events Due to COVID-19 Vaccines on Breakthrough Infections: Decentralized Observational Study With Underrepresented Groups

JMIR Form Res 2022;6(11):e41914

DOI: 10.2196/41914

PMID: 36309347

PMCID: 9640199

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

COVID-19 Vaccine reactogenicity and breakthrough infections: decentralized participatory study

  • Irene Gabashvili

ABSTRACT

A decentralized longitudinal study bridging digital divide identifies previously unreported patterns.


 Citation

Please cite as:

Gabashvili I

The Incidence and Effect of Adverse Events Due to COVID-19 Vaccines on Breakthrough Infections: Decentralized Observational Study With Underrepresented Groups

JMIR Form Res 2022;6(11):e41914

DOI: 10.2196/41914

PMID: 36309347

PMCID: 9640199

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.